Chong Kun Dang Pharmaceutical Corp.

Total Valuation

Chong Kun Dang Pharmaceutical Corp. carries a market capitalization of 910.47B, placing it among publicly traded companies globally. Its enterprise value stands at 1.26T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Chong Kun Dang Pharmaceutical Corp. currently has 13.18M shares outstanding.

Valuation Ratios

Chong Kun Dang Pharmaceutical Corp. trades at a trailing price-to-earnings ratio of 14.95. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at 1.50.

Enterprise Valuation

On an enterprise value basis, Chong Kun Dang Pharmaceutical Corp. trades at an EV/EBITDA multiple of 15.32 and an EV/FCF ratio of 3.73. The EV/Sales ratio of 0.72 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.32 provides insight into valuation relative to core operating earnings.

Financial Position

Chong Kun Dang Pharmaceutical Corp. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.77, indicating elevated leverage, while an interest coverage ratio of 11.50 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Chong Kun Dang Pharmaceutical Corp. posts a return on equity of 10.57 and a return on invested capital of 6.30.

Taxes

Over the trailing twelve months, Chong Kun Dang Pharmaceutical Corp. has paid 3.21B in income taxes, reflecting an effective tax rate of 3.93.

Stock Price Statistics

Chong Kun Dang Pharmaceutical Corp.'s stock has declined approximately -19.55763% over the past 52 weeks. The 50-day moving average sits at 76,922.00, while the 200-day moving average is 83,762.50.

Income Statement

Over the trailing twelve months, Chong Kun Dang Pharmaceutical Corp. generated 1.74T in revenue and converted that into 78.55B in net income, yielding earnings per share of 5,962.22. EBITDA reached 82.20B, while operating income came in at 82.20B.

Balance Sheet

Chong Kun Dang Pharmaceutical Corp. holds 285.23B in cash and equivalents against 368.00B in total debt, resulting in a net debt position of 183.86B. Total book value stands at 781.47B, with working capital of 522.64B providing operational flexibility.

Cash Flow

Chong Kun Dang Pharmaceutical Corp. produced 85.93B in operating cash flow over the past twelve months. After subtracting -245.16B in capital expenditures, free cash flow totaled -159.22B - equivalent to -12,082.99 per share.

Margins

Chong Kun Dang Pharmaceutical Corp. operates with a gross margin of 30.30, reflecting its pricing power and cost economics. The operating margin of 4.73 and net profit margin of 4.52 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Chong Kun Dang Pharmaceutical Corp.'s most recent stock split took place on December 27, 2024 with a 20:21 split ratio.

Scores

Chong Kun Dang Pharmaceutical Corp. posts an Altman Z-Score of 3.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.